Statins for renal patients: A fiddler on the roof?

International Journal of Nephrology

Volumn 2012, Issue , 2012, Pages

  Guedes, Anabela Malho ^a   Neves, Pedro Leão ^a  

^a HOSPITAL DE FARO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869066400     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2012/806872     Document Type: Review

References (39)

1. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 2004 351 13 1296 1370 2-s2.0-4644221457 10.1056/NEJMoa041031 (Pubitemid 39268908)
2. US Renal Data System, 2010 Annual data report. American Journal of Kidney Diseases 2011 57 supplement 1 e87 e98 10.1053/j.ajkd.2010.10.016
3. Stuveling E. M., Bakker S. J. L., Hillege H. L., de Jong P. E., Gans R. O. B., de Zeeuw D., Biochemical risk markers: a novel area for better prediction of renal risk? Nephrology Dialysis Transplantation 2005 20 3 497 508 2-s2.0-15044361399 10.1093/ndt/gfh680 (Pubitemid 40378417)
4. Castelli W. P., Anderson K., Wilson P. W. F., Levy D., Lipids and risk of coronary heart disease. The Framingham Study. Annals of Epidemiology 1992 2 1-2 23 28 2-s2.0-0026558610
5. Manttari M., Tiula E., Alikoski T., Manninen V., Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995 26 4 670 675 2-s2.0-0029166463
6. Muntner P., Coresh J., Smith J. C., Eckfeldt J., Klag M. J., Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney International 2000 58 1 293 301 2-s2.0-0033920866 10.1046/j.1523-1755.2000.00165.x (Pubitemid 30429874)
7. Ozsoy R. C., van der Steeg W. A., Kastelein J. J. P., Arisz L., Koopman M. G., Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrology Dialysis Transplantation 2007 22 6 1578 1586 2-s2.0-34447562972 10.1093/ndt/gfl790 (Pubitemid 47073755)
8. Campese V. M., Park J., HMG-CoA reductase inhibitors and the kidney. Kidney International 2007 71 12 1215 1222 2-s2.0-34249987651 10.1038/sj.ki.5002174 (Pubitemid 46884244)
9. Agarwal R., Effects of statins on renal function. Mayo Clinic Proceedings 2007 82 11 1381 1390 2-s2.0-35848945939 10.4065/82.11.1381 (Pubitemid 350060135)
10. Abrass C. K., Cellular lipid metabolism and the role of lipids in progressive renal disease. American Journal of Nephrology 2004 24 1 46 53 2-s2.0-1342344698 10.1159/000075925 (Pubitemid 38258276)
11. Samuelsson O., Mulec H., Knight-Gibson C., Attman P. O., Kron B., Larsson R., Weiss L., Wedel H., Alaupovic P., Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrology Dialysis Transplantation 1997 12 9 1908 1915 2-s2.0-0030865534 10.1093/ndt/12.9.1908 (Pubitemid 27379464)
12. Oda H., Keane W. F., Recent advances in statins and the kidney. Kidney International 1999 56 supplement 71 S-2 S-5 2-s2.0-0032976460 (Pubitemid 29304801)
13. Schaeffner E. S., Kurth T., Curhan G. C., Glynn R. J., Rexrode K. M., Baigent C., Buring J. E., Gaziano J. M., Cholesterol and the risk of renal dysfunction in apparently healthy men. Journal of the American Society of Nephrology 2003 14 8 2084 2091 2-s2.0-0041342004 (Pubitemid 36909916)
14. Shurraw S., Tonelli M., Statins for treatment of dyslipidemia in chronic kidney disease. Peritoneal Dialysis International 2006 26 5 523 539 2-s2.0-33750561096 (Pubitemid 44669427)
15. Ross R., Atherosclerosis: an inflammatory disease. New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
16. Mimic-Oka J., Simic T., Pljesa M., Oxidative modifications of plasma proteins in different stages of chronic renal failure. Medicine & Biology 2001 8 1 5
17. Stenvinkel P., Alvestrand A., Inflammation in end-stage renal disease: sources, consequences, and therapy. Seminars in Dialysis 2002 15 5 329 337 2-s2.0-0036719916 10.1046/j.1525-139X.2002.00083.x
18. Stenvinkel P., Heimbürger O., Lindholm B., Kaysen G. A., Bergström J., Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology Dialysis Transplantation 2000 15 7 953 960 2-s2.0-0342588054 (Pubitemid 30410364)
19. Vázquez-Pérez S., Aragoncillo P., De Las Heras N., Navarro-Cid J., Cediel E., Sanz-Rosa D., Ruilope L. M., Díaz C., Hernández G., Lahera V., Cachofeiro V., Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrology Dialysis Transplantation 2001 16 supplement 1 40 44 2-s2.0-0035016159 (Pubitemid 32492503)
20. Kalaitzidis R. G., Elisaf M. S., The role of statins in chronic kidney disease. American Journal of Nephrology 2011 34 3 195 202 2-s2.0-79960667212 10.1159/000330355
21. Sandhu S., Wiebe N., Fried L. F., Tonelli M., Statins for improving renal outcomes: a meta-Analysis. Journal of the American Society of Nephrology 2006 17 7 2006 2016 2-s2.0-33745836406 10.1681/ASN.2006010012 (Pubitemid 44036185)
22. Douglas K., O'Malley P. G., Jackson J. L., Meta-analysis: the effect of statins on albuminuria. Annals of Internal Medicine 2006 145 2 117 124 2-s2.0-33746673912 (Pubitemid 46780585)
23. Strippoli G. F. M., Navaneethan S. D., Johnson D. W., Perkovic V., Pellegrini F., Nicolucci A., Craig J. C., Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. British Medical Journal 2008 336 7645 645 651 2-s2.0-41449093519 10.1136/bmj.39472.580984.AE (Pubitemid 351481234)
24. Vidt D. G., Cressman M. D., Harris S., Pears J. S., Hutchinson H. G., Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004 102 1 52 60 2-s2.0-1842829905 10.1159/000077704 (Pubitemid 38490263)
25. McKenney J. M., Davidson M. H., Jacobson T. A., Guyton J. R., Final conclusions and recommendations of the national lipid association statin safety assessment task force. American Journal of Cardiology 2006 97 supplement 8 S89 S94 2-s2.0-33645889332 10.1016/j.amjcard.2006.02.030
26. Athyros V. G., Mikhailidis D. P., Papageorgiou A. A., Symeonidis A. N., Pehlivanidis A. N., Bouloukos V. I., Elisaf M., The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Journal of Clinical Pathology 2004 57 7 728 734 2-s2.0-1542298565 10.1136/jcp.2003.012989 (Pubitemid 38901488)
27. Koren M. J., Davidson M. H., ALLIANCE Investigators. Impact of aggressive treatment with atorvastatin in renal function in managed care patients with coronary heart disease: the ALLIANCE study [abstract 1070-123]. Journal of the American College of Cardiology 2005 45 supplement A 391A 10.1016/j.jacc.2004.10. 038 (Pubitemid 40186790)
28. Tonelli M., Moyé L., Sacks F. M., Cole T., Curhan G. C., Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. Journal of the American Society of Nephrology 2003 14 6 1605 1613 2-s2.0-0038512398 10.1097/01.ASN.0000068461. 45784.2F (Pubitemid 36687063)
29. Baigent C., Landray M. J., Reith C., Emberson J., Wheeler D. C., Tomson C., Wanner C., Krane V., Cass A., Craig J., Neal B., Jiang L., Hooi L. S., Levin A., Agodoa L., Gaziano M., Kasiske B., Walker R., Massy Z. A., Feldt-Rasmussen B., Krairittichai U., Ophascharoensuk V., Fellström B., Holdaas H., Tesar V., Wiecek A., Grobbee D., De Zeeuw D., Grönhagen-Riska C., Dasgupta T., Lewis D., Herrington W., Mafham M., Majoni W., Wallendszus K., Grimm R., Pedersen T., Tobert J., Armitage J., Baxter A., Bray C., Chen Y., Chen Z., Hill M., Knott C., Parish S., Simpson D., Sleight P., Young A., Collins R., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 2011 377 9784 2181 2192 2-s2.0-79959746706 10.1016/S0140-6736(11)60739-3
30. Prospective evaluation of proteinuria and renal function in diabetic patients with progressive renal disease. Proceedings of the 47th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress June 2010 Munich, Germany
31. Olyaei A., Greer E., Delos Santos R., Rueda J., The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Clinical Journal of the American Society of Nephrology 2011 6 3 664 678 2-s2.0-79952997878 10.2215/CJN.09091010
32. Keller D. M., PLANET I and II: atorvastatin beats rosuvastatin for protecting kidneys in diabetic and nondiabetic patients. http://www.theheart. org/article/1095269.do, 2012
33. Tonelli M., Isles C., Curhan G. C., Tonkin A., Pfeffer M. A., Shepherd J., Sacks F. M., Furberg C., Cobbe S. M., Simes J., Craven T., West M., Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004 110 12 1557 1563 2-s2.0-20844462717 10.1161/01.CIR.0000143892. 84582.60 (Pubitemid 39297976)
34. Neves P. L., Malho A., Cabrita A., Pinho A., Baptista A., Morgado E., Faísca M., Carrasqueira H., Silva A. P., Statins and vitamin D: a friendly association in pre-dialysis patients. International Urology and Nephrology 2010 42 1 173 179 2-s2.0-77950916104 10.1007/s11255-009-9634-x
35. Wanner C., Kane V., Marz W., for German diabetes and dialysis study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The New England Journal of Medicine 2005 353 238 248 10.1056/NEJMoa043545 (Pubitemid 41058323)
36. Fellström B. C., Jardine A. G., Schmieder R. E., for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. The New England Journal of Medicine 2009 360 1395 1407 10.1056/NEJMoa0810177
37. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
38. Goldsmith D., Covic A. C., Editorial: Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD. International Urology and Nephrology 2010 42 1 133 136 2-s2.0-77950868012 10.1007/s11255-009-9649-3
39. März W., Genser B., Drechsler C., Krane V., Grammer T. B., Ritz E., Stojakovic T., Scharnagl H., Winkler K., Holme I., Holdaas H., Wanner C., Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical Journal of the American Society of Nephrology 2011 6 6 1316 1325 2-s2.0-79958244625 10.2215/CJN.09121010